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Villejuif, France.Understanding the molecular mechanisms leading embry-
onic mesoblastic stem cells to be recruited towards a
specific lineage and thereafter to develop the correspond-
ing differentiation programme towards its endstage is a
major challenge of today’s biology. These processes clearly
depend on both autonomous genetic programmes and
environmental signals. The characterization of the respec-
tive contributing factors is of interest in both fundamental
and medical research. The availability of pluripotent and
inducible progenitor cell lines would greatly facilitate the
identification of the autocrine and paracrine signals
involved in the recruitment towards a given lineage
and in the implementation of a complete differentiation
programme.
Multipotential embryonic stem cells (ES) and embryonal
carcinoma cells (EC) which are able to differentiate into
derivatives of the three germ layers have provided in vitro
differentiation model systems1,2. However, molecular
studies using these systems remain difficult because of the
heterogeneity of differentiation and of the short life span of
the differentiated daughter cells. In an attempt to isolate
lineage progenitor cell lines, we have transfected multi-
potential embryonal carcinoma cells with an immortalizing
plasmid, pK4 which contains the early genes of SV40 under
the control of the promoter of the E1A adenovirus, a virus
known to be active early in mouse development3. Upon
induction of differentiation of the multipotential cells, neuro-
ectodermal, endodermal or mesodermal precursor cell
lines were immortalized. The low level of constitutive
expression of the SV40 T antigen promotes immortaliz-
ation of the committed progenitors while still allowing
differentiation along multiple pathways to occur4–6.
One such derived cell line, C1, behaves as a meso-
dermal progenitor. It derives from a 1003-pK4 EC cell line
and was selected from a teratocarcinoma island of cells
resembling the somitic mesoderm. C1 cells maintain a
stable undifferentiated phenotype under long-term stan-
dard culture conditions. Depending on the type of induction,
C1 cells are capable of differentiating in vitro at high
frequency (>80%) into mature cells, either osteocytes,
chondrocytes or adipocytes7. C1 cells can also be con-
verted into myoblasts capable of giving rise to myofibres
upon treatment by 5-azacytidine (unpublished obser-
vations). As in the case of C3H10T1/2 cell line, theS85frequency of myogenic differentiation never exceeds 25%
and co-differentiations into fat (15%) and cartilage (1%) are
also observed8,9. The differentiation steps of the C1 meso-
blastic clone are summarized in Fig. 1. In sparse cultures,
Cl cells expresses a series of genes transcribed in embry-
onic mesodermal stem cells during somites, sclerotome or
limb bud development7 but they do not express any osteo-
genic, chondrogenic or adipogenic markers. Cell–cell inter-
actions are required prior to any recruitment towards
differentiation. These contacts turn on the expression of the
early genes of the three programmes and renders the
committed Cl cells competent to enter a particular pathway
in response to specific extracellular signals. Mesodermal
condensation is a prerequisite for skeletal embryonic devel-
opment to take place10. Accordingly, nodule formation is
required for Cl cells osteogenic or chondrogenic differen-
tiation. Noteworthy, C1 competent cells are still at a precur-
sor stage since they never spontaneously differentiate.
Thereafter, the cells need instructive signals to enter a
particular programme, adopt a defined identity and reach
the terminal stages of osteogenic, chondrogenic or adipo-
genic differentiation. Each pathway follows a reproducible
schedule divided into distinct lineage-specific stages based
on the temporal regulation of gene expression. In response
to ascorbic acid (AA) (50 g/ml) and -glycerophosphate
(GP) (10 mM), close to 100% of the nodules secrete a type
I collagen extracellular matrix (ECM) which progressively
mineralizes forming apatite crystals6,11. Upon chronic
exposure to DEX (10−6 M), 80% of the nodules become
recruited towards chondrogenesis. C1-derived chondro-
cytes first build up an ECM composed of type II collagen
and aggrecan and then convert into hypertrophic chondro-
cytes7. Finally when cultured in monolayers, confluent C1
cells differentiate into functional adipocytes under the syn-
ergistic action of DEX (10−7 M) and insulin (10−6 M). After
15 days of treatment, more than 80% of the cells contain
lipid droplets7.
The availability of a tripotential and inducible mesoblastic
cell line may help to dissect the interplay between the
autocrine and paracrine signals underlying mesoblast
recruitment and differentiation and to gain insight into the
role of the extracellular matrix (ECM) in the establishment
of a differentiated phenotype. The present paper focuses
on the chondrogenic programme of the C1 cells and
illustrates how an intrinsic genetic programme once
recruited by epigenetic signals can proceed autonomously.
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MESOBLASTIC PRECURSOR SYNTHESIZES AND SECRETES THE
ENTIRE SET OF COLLAGENS REQUIRED IN VIVO TO INITIATE BONE,
CARTILAGE OR ADIPOCYTE DIFFERENTIATION
Although the precise mechanisms by which ECM con-
tributes to cellular differentiation are still poorly understood,
many evidences from genetic diseases, in vitro studies, or
gene inactivation experiments indicate that onset and
maintenance of chondrocytic or osteoblastic phenotype
depend, at least in part, on controls related to normal
collagen matrix assembly. Validation of an in vitro
system therefore requires that temporal changes in
collagen expression and assembly fulfill the criteria of the
lineage-dependent ECM formation observed in vivo.
A remarkable property of the C1 precursor cells is their
ability to co-express type I, II, III, V, VI, XI collagens and to
synthesize this set of collagen proteins, as soon as they
have established contact. This initial step of commitment is
reversible since transcription of collagen-specific genes
can be shut down upon dissociation of the cells7,11. At this
stage, the mesoblastic cells are still determined since they
have not yet chosen a fate. The neosynthesized collagens
are secreted and remain soluble in the extracellular
space12. Only those collagens which participate in the early
phases of each of the three programmes are present; for
instance, type IX and X col, the markers of overt chondro-
genesis, are not expressed. Little is known on the reper-
toire of collagen molecules expressed by an embryonic or
an adult mesodermal stem cell. As C1 cells, the mesen-
chymal precursors which condense during early embryo-
genesis are known to produce type I and type II col at
basal levels13. These precursors also contain type XI
col mRNA14. Type II col transcripts are also found in fetal
calvaria and in periosteal cells of the mandible15. Type VI
col cDNA has been cloned from an adipogenic precursor
cell line16. The C1 cells as competent progenitors already
express a set of collagens required in vivo to initiate the
building up of a bone or cartilage ECM. The onset of a
differentiation programme therefore implies controls acting
at the pre- and/or post-translational levels that direct the
expression of a unique set of collagens characteristic of
one particular fate of the C1 cells. Actually, implementation
of the C1 osteogenic, chondrogenic or adipogenic pro-
grammes up to their terminal stages involves profiles of
collagen expression and ECM assembly close to those
documented in vivo12.Fig. 1. The differentiation steps of the C1 mesodermal progenitor cell.C1 CELLS RECAPITULATE IN VITRO THE STAGES OF
CHONDROCYTE DIFFERENTIATION OBSERVED IN THE GROWTH
PLATE OF LONG BONES
In vivo, chondrogenesis occurs through a progression
from mesenchymal precursors to hypertrophic chondro-
cytes, each step along the way being characterized by the
biochemical properties of the maturing chondrocytes as
well as the composition of the ECM they elaborate. The
analysis of collagen mRNAS, protein synthesis and
assembly into the ECM during the C1 chondrogenic pro-
gramme, reveals that the C1 cells progress through distinct
stages which resemble the phenotypic transitions spatially
observed in the growth plate of the long bones7,12.
Upon chronic exposure to dexamethasone (DEX)
(10−6 M) in a medium supplemented with 1% fetal calf
serum, 80% of the nodules are recruited towards chondro-
genesis. After 25 days of treatment, the cells acquire
properties evocative of the proliferative zone chondrocytes.
Type II collagen becomes the major collagen produced, its
level of neosynthesis increases by a factor of 20 compared
with the competent progenitor. Therefore, C1 cells possess
the necessary controls to preclude any deposition of type I
collagen in the cartilage matrix.
From day 40 of DEX treatment, the cells enlarge and
build up a profuse ECM with collagens type II, XI and
aggrecan, typical of the mature chondrocytes of the growth
plate. All the neosynthesized type II collagen is now
sequestered within the nodules. Type I collagen synthesis
is virtually abolished (Fig. 2).
After day 60 of DEX treatment, the cells acquire within
2 weeks the typical in vivo properties of hypertrophic
chondrocytes13. Despite the presence of the immortalizing
plasmid, the C1 cells lose their proliferative potential as
revealed by the lack of PCNA staining or labelling with 3H
thymidine12. A decrease in the total amount of neosynthe-
sized type II collagen is observed and the corresponding
matrix fades out in most aggregates. The amount of aggre-
can also diminishes. This selective degradation of the
matrix has been reported to accompany the course of
endochondral ossification and to be mediated by metallo-
proteinases such as MMP2 and MMP1317,18. The C1
model may prove useful to explore the role of these
metalloproteinases in the terminal phase of the chondro-
genic program. The C1 hypertrophic-like cells elaborate a
type X collagen matrix and display increased alkaline
phosphatase activity. In addition, a subpopulation of
Osteoarthritis and Cartilage Vol. 9 Suppl. A S87hypertrophic-like cells acquire osteoblast-like functions:
they synthesize de novo type I collagen which, in contrast
with the early stages of chondrocyte differentiation, is
deposited in the ECM in parallel with osteopontin (Fig. 2).
Treatment of hypertophic-like C1 cells with ascorbic acid
(50 g/ml) and -GP (8 mM) appears to promote calcifi-
cation of the cartilage matrix. Von Kossa staining of aggre-
gate section shows that the apatite crystal deposits are
strictly associated with the hypertrophic areas expressing
type X collagen (unpublished observations).
Thus, provided they are cultivated in the presence of 1%
FCS and chronically treated by DEX (10−6 M), the C1 cells
are able to undergo at high frequency a self-organizing
progression of progenitor recruitment, proliferation,
maturation, hypertrophy and even post-hypertrophy as
observed for the growth plate chondrocytes of the long
bones. Furthermore, like the epiphyseal chondrocytes, they
also seem to be able to initiate mineralization.
Cellular models amenable to perturbation such as C1
are aimed at bringing answers to fundamental questions on
the signaling pathways governing the entry and progres-
sion of precursor cell into a genetic differentiation pro-
gramme. Our results clearly indicate that the C1
mesodermal cells are forced to select chondrogenesis out
of three lineages, under the single action of DEX 10−6 M
and 1% fetal calf serum (FCS).ADDITION OF ASCORBATE IN COMBINATION WITH DEX DOES NOT
ACCELERATE THE CHONDROGENIC PROGRAMME
Upon DEX addition, a delay exists between type II
collagen mRNA expression and the deposition of the pro-
tein in the ECM. Indeed, after 10 days of DEX treatment,
type II collagen mRNA expression and protein synthesis
have increased. A type II collagen matrix formation initiating
at discrete focal sites within the aggregates is however
not observed until day 30. Possibly the cells need thepresence, or the absence, of (an) additional factor(s) to
accelerate type II collagen fibril assembly. We have tested
the effect of AA (50 g/ml) on the onset of the C1 chondro-
genic programme. This molecule is known to favor collagen
processing and secretion and could therefore affect the
differentiation programme by promoting a permissive
environment for tissue-specific gene expression. Addition
of AA with DEX to the progenitor nodules does not modify
the kinetics of type II collagen assembly observed in the
sole presence of DEX; 30 days of DEX treatment are still
required for the cells to elaborate an ECM essentially made
of type II collagen. The small amount of type I collagen
neosynthesized remains excluded from the ECM and
secreted in the culture medium. It is interesting to note that
AA does not promote extensive mobilization of type I
collagen fibres in the matrix. This could have been
expected since AA is used with GP to promote C1
osteogenic differentiation. By contrast addition of AA on C1
precursor cells promotes adipogenesis. Indeed, when nod-
ules of C1 cells are exposed to both DEX (10−6 M) and AA,
clusters of adipocytes become reproducibly apparent within
the chondrogenic nodules. This effect of AA as an activator
of adipose cell differentiation was previously reported19.
Thus AA is not required to recruit the C1 cells towards
chondrogenesis. It does not improve the response of the
C1 cells to DEX and does not reduce the time course of
type II collagen matrix formation during the early stage of
chondrogenesis. Once type II collagen matrix deposition
has been initiated, AA favours the elaboration of denser
type II collagen network, in agreement with its postulated
role20.Fig. 2. Phenotypic conversion of C1 mature chondrocytes into hypertrophic-like cells. Indirect immunoperoxydase labelling of aggregates
sections at day 60 (A,B,C) and day 80 (D,E,F) with: (A, D): anti-type II collagen antibody. (B, E): anti-type X collagen antibody. (C, F) anti-type
I collagen antibody.DEXAMETHASONE IS A DOMINANT SIGNALLING MOLECULE FOR
THE RECRUITMENT OF THE C1 PRECURSOR CELLS
The role of DEX as a directive signal to recruit the C1
progenitor towards chondrogenesis was further established
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differentiation to proceed in a serum-free environment
(unpublished observations). In these conditions, as in the
presence of 1% serum, the cells start to elaborate a type II
collagen and aggrecan-rich extracellular matrix after 4
weeks of DEX treatment (Fig. 3). The most striking differ-
ence with the serum supplemented conditions resides
in the homogeneity of the differentiation process. The
chondrogenic differentiation concerns close to 100% of the
aggregates (versus 80% in the presence of 1% serum).
Furthermore, within the aggregates, the majority of cells
resemble typical chondrocytes as inferred by the mor-
phology and extensive deposition of type II collagen and
aggrecan in the ECM (Fig. 3). These observations demon-
strate that DEX alone is the dominant signalling molecule
mediating the recruitment of the C1 progenitor towards the
mature chondrocyte phenotype. The homogeneity of differ-
entiation in serum-free versus serum-containing culture
conditions, likely reflects a more efficient recruitment of the
precursor cells. Thus virtually all C1 progenitor cells seems
competent to respond to DEX but factors(s) present in the
serum can interfere with the inducing signal(s) mediated
by DEX.
By itself, however, DEX is not sufficient to promote
efficient conversion of the C1 mature chondrocyte towards
its terminal state of differentiation. Indeed, (i) type X colla-
gen is never detected as an extensive organized network
within the extracellular space and (ii) the typical increase in
alkaline phosphatase activity that in vivo, goes along with
acquisition of the hypertrophic phenotype is not observed in
the DEX-treated aggregates. Nevertheless, the chondro-
genic programme does not seem totally arrested since C1
chondrocytes still express type X collagen transcripts from
day 30 (as in 1% serum) and in some aggregates, the
corresponding protein is detected at day 50 around some
enlarge, hypertrophic-like cells. This suggests that, in the
absence of serum, factor(s) are either lacking or in rate-limiting concentration to efficiently trigger the phenotypic
conversion to an overt hypertrophic state. Triiodothyronine
(T3) treatment permits effective type X collagen assembly
in the ECM as well as expression of osteoblast-like func-
tions (unpublished observations). Whether T3 promotes the
entry of the mature chondrocyte into the hypertrophic state
or acts as a positive regulator of the hypertrophic cell
functions remains to be further investigated.Fig. 3. C1 cell chondrogenic phenotype in serum-free medium. Sections of aggregates treated for 30 days with DEX (10−6 M). (A) Indirect
immunoperoxydase labelling with an anti-type II collagen antibody. (B) Alcian blue staining of cartilage proteoglycan.PERSPECTIVES AND CONCLUSIONS
Skeletal development is a multi-step process involving
the patterning of the embryonic skeleton and the control of
the differentiation programmes of precursor cells commit-
ted to the cartilage or bone lineage. Differentiation of
osteoblasts or chondroblasts and the subsequent selective
and temporal ECM deposition must be intimately
co-ordinated with the timing of skeletal morphogenesis.
Recent work by a number of groups has begun to unravel
intricate regulatory signalling mechanisms involved in
chondrogenesis. For instance, Ihh, BMPs, PTH/PTHrP and
Delta have been shown to participate in the control of the
chondrogenic programme21–25. RT-PCR analyses show
that C1 progenitor cells express transcripts for BMP 2, BMP
4, Ihh as well as receptors for BMP (BMPR IA and BMPRII)
and PTH/PTHrP (PTH/PTHrPR). Interestingly, the level of
expression of all these genes appears dependent on the
nature of cellular interactions (sparse/monolayer/aggregate
cultures) (Fig. 4). Thus C1 cells transcribe several
autocrine factors important for the implementation of the
chondrogenic programme and/or possess the receptors to
respond to their signalling, prior to their choice of fate.
Expression of these genes is thereafter regulated in a
lineage- and temporal-dependent manner during the
osteogenic, adipogenic or chondrogenic differentiation
(unpublished observations).
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signalling pathway requires an appreciation of how this
signal is integrated with other autocrine or paracrine signals
received by the cell. In vitro differentiation models provide
essential tools in this context. In the C1 system, one given
signalling pathway can be studied in direct relation with the
stage of chondrocyte differentiation since C1 chondro-
genesis is implemented through distinct differentiation
steps characterized by specific patterns of collagen expres-
sion and ECM deposition. Obtention of serum-free culture
conditions ensuring in vitro chondrogenesis, will facilitate
the dissection of the complex mechanisms involved in the
recruitment and progression of the intrinsic differentiation
programmes of a mesodermal progenitor.Acknowledgments
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